title: [Recent studies on anti-angiogenesis in cancer therapy].
abstract: Angiogenesis is known to be a critical process for the tumor growth and metastasis. There are many indigenous role-players in tumor angiogenesis and anti-angiogenesis, where tumor-host interaction may work. A lot of agents with anti-angiogenic activity have been developed for anti-cancer treatment. Several agents including Marimastat, Primostat, Neovastat, Bay-12-9566m, Interferon-alpha, SU101, retinoids, and IM862, are/were under phase-three study. There are still many future-promising results of basic or clinical studies on inhibitors of MMPs, and inhibitors of VEGF/R, Endostatin, somatostatin analogues, COX-2 inhibitors, and others. Most of the combination treatments of antiangiogenetic agent and conventional anticancer agents therapy, or radiation therapy as we reported, showed relatively small or minute increase in toxicity of these cytotoxic treatments.
authors.affiliation: Department of Radiology, Wakayama Medical College.
authors.forename: K
authors.initials: K
authors.lastname: Kishi
authors.forename: L
authors.initials: L
authors.lastname: Milas
authors.forename: N
authors.initials: N
authors.lastname: Hunter
authors.forename: M
authors.initials: M
authors.lastname: Sato
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000502:physiology; D006801:Humans; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000502:physiology; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000502:physiology; D009369:Neoplasms / Q000098:blood supply / Q000628:therapy*; D009389:Neovascularization, Pathologic; D011720:Pyrazoles / Q000627:therapeutic use; D011878:Radiotherapy; D013449:Sulfonamides / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000096926:Benzenesulfonamides
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D016228:Endothelial Growth Factors; D008222:Lymphokines; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases; D011720:Pyrazoles; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C119130:4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; D000096926:Benzenesulfonamides